Short Interest in Apollomics, Inc. (NASDAQ:APLM) Drops By 10.3%

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 21,800 shares, a decline of 10.3% from the November 30th total of 24,300 shares. Based on an average trading volume of 305,800 shares, the short-interest ratio is currently 0.1 days. Currently, 3.2% of the shares of the company are short sold.

Apollomics Price Performance

APLM opened at $10.13 on Tuesday. Apollomics has a 1-year low of $6.50 and a 1-year high of $105.00. The business has a 50 day moving average of $10.91 and a 200-day moving average of $14.39.

Hedge Funds Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC boosted its stake in Apollomics, Inc. (NASDAQ:APLM) by 247.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,259,117 shares of the company’s stock after buying an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned approximately 1.41% of Apollomics worth $179,000 at the end of the most recent quarter. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.